Patents by Inventor Tonis Timmusk
Tonis Timmusk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190153052Abstract: A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof.Type: ApplicationFiled: October 17, 2014Publication date: May 23, 2019Applicant: HERANTIS PHARMA PLC.Inventors: Mart SAARMA, Juha LAUREN, Päivi LINDHOLM, Tonis TIMMUSK, Raimo TUOMINEN
-
Publication number: 20170057948Abstract: A tropomyosin receptor kinase (Trk) antagonist having a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is CH3, R2 is OCH3, R3 is SO2N(CH3)2, and R4 is H; or R1 is CH3, R2 is OH, R3 is SO2N(CH3)2, and R4 is H.Type: ApplicationFiled: August 27, 2016Publication date: March 2, 2017Inventors: Tonis Timmusk, Margus Lopp, Eero Vasar, Allen Kaasik, Mati Karelson
-
Patent number: 9127082Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.Type: GrantFiled: February 26, 2008Date of Patent: September 8, 2015Assignee: HERANTIS PHARMA PLC.Inventors: Mart Saarma, Juha Lauren, Paivi Lindholm, Tonis Timmusk, Raimo Tuominen
-
Patent number: 8980821Abstract: A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof.Type: GrantFiled: April 15, 2011Date of Patent: March 17, 2015Assignee: Herantis Pharma OyjInventors: Mart Saarma, Juha Lauren, Päivi Lindholm, Tonis Timmusk, Raimo Tuominen
-
Publication number: 20110251132Abstract: A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof.Type: ApplicationFiled: April 15, 2011Publication date: October 13, 2011Inventors: Mart SAARMA, Juha Lauren, Päivi Lindholm, Tonis Timmusk, Raimo Tuominen
-
Publication number: 20100285045Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.Type: ApplicationFiled: December 14, 2006Publication date: November 11, 2010Applicant: Licentia LtdInventors: Mart Saarma, Juha Lauren, Paivi Lindholm, Tonis Timmusk, Raimo Tuominen, Merja Voutilainen
-
Patent number: 7488588Abstract: The present invention discloses purified and isolated nucleic acid sequences encoding polypeptides having a structure substantially similar to that of splicing forms of mammalian GFR?4 comprising the amino acid sequence (SEQ ID NO:1:)-(SEQ ID NO:6:). The preferred sequences comprise cDNAs having the sequence (SEQ ID NO:7:)-(SEQ ID NO:13:). The present invention is also related to purified and isolated polypeptides comprising the amino acid sequence and or substantially similar splicing forms of mammalian GFRà4. Furthermore, the invention is related to substances capable of specifically recognizing said polypeptides and including both antibodies and receptors. The active compounds of the present invention including cDNAS, polypeptides, binding substances, and antibodies.Type: GrantFiled: November 14, 2000Date of Patent: February 10, 2009Assignee: Licentia Ltd.Inventors: Matti Airaksinen, Mart Saarma, Dimitri Poteriaev, Maria Lindahl, Tönis Timmusk, Jari Rossi
-
Patent number: 7452969Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.Type: GrantFiled: August 27, 2003Date of Patent: November 18, 2008Assignee: Licentia LtdInventors: Mart Saarma, Juha Lauren, Päivi Lindholm, Tonis Timmusk, Raimo Tuominen
-
Publication number: 20080269154Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.Type: ApplicationFiled: February 26, 2008Publication date: October 30, 2008Applicant: Licentia Ltd.Inventors: Mart SAARMA, Juha Lauren, Paivi Lindholm, Tonis Timmusk, Raimo Tuominen
-
Publication number: 20060195915Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.Type: ApplicationFiled: January 12, 2006Publication date: August 31, 2006Applicant: Licentia Ltd.Inventors: Mart Saarma, Juha Lauren, Paivi Lindholm, Tonis Timmusk, Raimo Tuominen
-
Publication number: 20060160103Abstract: The disclosure relates to isolated polynucleotides and purified polypeptides of the Neu family of proteins, which have been shown to demonstrate transcriptional regulatory activity. For example, the purified polynucleotide can encode a Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. A purified Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. Antibodies capable of specifically binding to the disclosed Neu polypeptides are disclosed. Vectors expressing the disclosed Neu protein coding regions and host cells containing the vectors are disclosed. Methods of making the Neu proteins disclosed are also provided, as are method of identifying binding partners that interact with a Neu protein family member.Type: ApplicationFiled: May 9, 2005Publication date: July 20, 2006Inventors: Kaia Palm, Tonis Timmusk
-
Publication number: 20060084619Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.Type: ApplicationFiled: August 27, 2003Publication date: April 20, 2006Inventors: Mart Saarma, Juha Lauren, Paivi Lindholm, Tonis Timmusk, Raimo Tuominen
-
Patent number: 6962985Abstract: The disclosure relates to isolated polynucleotides and purified polypeptides of the Neu family of proteins, which have been shown to demonstrate transcriptional regulatory activity. For example, the purified polynucleotide can encode a Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. A purified Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. Antibodies capable of specifically binding to the disclosed Neu polypeptides are disclosed. Vectors expressing the disclosed Neu protein coding regions and host cells containing the vectors are disclosed. Methods of making the Neu proteins disclosed are also provided, as are method of identifying binding partners that interact with a Neu protein family member.Type: GrantFiled: March 14, 2001Date of Patent: November 8, 2005Assignee: CeMines, Inc.Inventors: Kaia Palm, Tonis Timmusk
-
Publication number: 20020132293Abstract: The disclosure relates to isolated polynucleotides and purified polypeptides of the Neu family of proteins, which have been shown to demonstrate transcriptional regulatory activity. For example, the purified polynucleotide can encode a Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. A purified Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. Antibodies capable of specifically binding to the disclosed Neu polypeptides are disclosed. Vectors expressing the disclosed Neu protein coding regions and host cells containing the vectors are disclosed. Methods of making the Neu proteins disclosed are also provided, as are method of identifying binding partners that interact with a Neu protein family member.Type: ApplicationFiled: March 14, 2001Publication date: September 19, 2002Inventors: Kaia Palm, Tonis Timmusk